gilead is committed to ensuring that a drug's price is never a barrier to access. we support a number of programs that help ensure patients who need our therapies have access to them.
Keywords to Search:
Company Address:
333 Lakeside Dr,FOSTER CITY,CA,USA
ZIP Code: Postal Code:
94404-1147
Telephone Number:
6505789264 (+1-650-578-9264)
Fax Number:
6505743000 (+1-650-574-3000)
Website:
www. gilead. com
Email:
USA SIC Code(Standard Industrial Classification Code):
copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Gilead Sciences Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer inflammation
Gilead Sciences: Company Learn about the biopharmaceutical company Gilead Sciences, including mission, vision, values, history, impact, leadership, therapeutic areas and other information
Gilead Sciences, Inc. - Investor Relations At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in
Gilead Sciences Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need
U. S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly . . . FOSTER CITY, Calif --(BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) today announced that the U S Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP)
Medicines - Gilead Sciences Access the list of approved Gilead therapies across virology including HIV, liver disease including hepatitis and primary biliary cholangitis, oncology inflammation
U. S. FDA Grants Breakthrough Therapy Designation to Trodelvy . . . FOSTER CITY, Calif --(BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) today announced that the U S Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy ® (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has
Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial . . . FOSTER CITY, Calif --(BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024 “Gilead delivered another exceptionally strong full year and fourth quarter, with growth in our base business product sales of 8% for 2024 and 13% year-over-year for the fourth
Gilead and Genesis Therapeutics Announce Strategic Collaboration to . . . FOSTER CITY, Calif BURLINGAME, Calif --(BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) and Genesis Therapeutics, Inc announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets